Medtronic vs Pfizer

XRlabs Raises €7.48M for AI Surgical Intelligence

London-based XRlabs, a Surgical Intelligence company founded by neurosurgeon Dr. Ali Haddad, has raised €7.48 million ($8.4 million) in Seed funding. The round was led by Playground Global (Palo Alto), with participation from London-based HealthTech investor Eka Ventures. The company develops modular, device-agnostic software that uses computer vision and deep learning to transform live surgical video, navigation telemetry, and pre-operative imaging into a real-time, anatomy-aware view. Its platform has been deployed in over 100 surgical cases across three continents. The funding will support engineering and clinical team expansion, regulatory advancement in the UK, EU, and US, and the extension of clinical evidence. XRlabs also announced Omar Ishrak, former CEO of Medtronic, as Chair of its Board. The company has been awarded compute allocation on the UK AI Research Resource (AIRR).

• XRlabs raised €7.48 million ($8.4 million) in Seed funding led by Playground Global with participation from Eka Ventures.
• Omar Ishrak, former CEO of Medtronic, joined as Chair of XRlabs' Board of Directors.
• The company's platform has been deployed in over 100 surgical cases on three continents.

8-K Financial Filing Analysis for Medtronic (2026-09-01)

On September 1, 2026, Medtronic plc filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing its financial results for the first quarter of fiscal year 2027. The details of the quarterly performance were furnished via press release in Exhibit 99.1, signed by Executive Vice President and Chief Financial Officer Thierry Piéton.

• Medtronic plc furnished its Q1 FY2027 financial results via Form 8-K on September 1, 2026.
• The earnings announcement is furnished under Item 2.02 with details provided in Exhibit 99.1.
• The filing was formally authorized and signed by Executive Vice President and CFO Thierry Piéton.

Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.

Medtronic plc (Medtronic; NYSE: MDT) today announced the final exchange ratio for its previously announced offer to exchange outstanding Medtronic ordinary shares for shares of common stock of MiniMed Group, Inc.

10-Q Financial Filing Analysis for Pfizer (2026-08-04)

Pfizer Inc. reported its second-quarter 2026 financial results, with total revenues rising 3% year-over-year to $15.03 billion (up 1% operationally). Operational expansion was led by core franchises including Eliquis (+19% operationally to $2.43 billion), Padcev (+23% operationally to $667 million), and the Vyndaqel family (+8% operationally to $1.76 billion), which offset steep declines in COVID-19 product revenues (Paxlovid down 95% operationally to $21 million; Comirnaty down 34% operationally to $261 million). The company reported a net loss attributable to common shareholders of $(248) million for Q2 2026, compared to net income of $2.91 billion in Q2 2025. This downturn was driven by $4.33 billion in pre-tax intangible asset impairment charges (including $3.8 billion for sigvotatug vedotin following unfavorable Phase 3 trial results and $525 million for Oxbryta), alongside $842 million in legal charges, partially offset by a $1.87 billion net gain on the exit of its ViiV Healthcare investment. Pfizer also expanded its enterprise-wide cost realignment and manufacturing optimization programs, targeting total net cost savings of approximately $6.7 billion and $3.0 billion, respectively, through 2029.

• Q2 2026 total revenues reached $15.03 billion, up 3% YoY (5% operational growth excluding COVID-19 products Comirnaty and Paxlovid).
• Net loss attributable to common shareholders was $(248) million, heavily impacted by $4.325 billion in intangible asset impairments ($3.8 billion for IPR&D sigvotatug vedotin and $525 million for Oxbryta) and $842 million in legal charges.
• Pfizer completed the sale of its 11.7% stake in ViiV Healthcare for $1.875 billion in cash proceeds, realizing a pre-tax net gain of $1.870 billion.

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Investor Presentation Released: Pfizer

AI parsed presentation narrative: Pfizer is demonstrating steady execution and financial outperformance by exceeding revenue and EPS expectations despite the decline in COVID-19 product sales. Management's central thesis focuses on maximizing the value of key acquisitions like Seagen and Metsera to drive post-2028 growth through a high single-digit revenue CAGR and a robust pipeline in oncology and obesity. Key tailwinds mentioned: Acquisition Integration Success, Obesity Pipeline Advancement.